TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05579847

Intervention type: BEHAVIORAL
Intervention: European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire
Description: The European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C-30) comprises 30 single questions, 24 of which are aggregated into nine multi-item scales, that is, five functioning scales (physical, role, cognitive, emotional and social), three symptom scales (fatigue, pain and nausea/vomiting) and one global health status scale. The remaining six single-item (dyspnea, appetite loss, sleep disturbance, constipation, diarrhea and the financial impact) scales assess symptoms. No item occurs in more than one scale.~Scoring of the QLQ-C30 is performed according to QLQ-C30 Scoring manual. All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status denote a better level of functioning (i.e. a better state of the patient), while higher scores on the symptom and single-item scales indicate a higher level of symptoms (i.e. a worse state of the patient).

Intervention type: BEHAVIORAL
Intervention: Patient Post Intervention Survey
Description: The Patient Post Intervention Survey is a 7 question survey to help determine the effectiveness of the mHealth app. 3 questions are open fields for patient feedback, and 4 questions ask how often the app was used, how often the educational module was used and if the patient found it useful.
Study: NCT04600336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin Chloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin Chloride
Description: Given PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06024993

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flow-controlled ventilation (FCV)
Description: 20 minutes of FCV, delivered with the CE-marked Evone ventilator (Ventinova medical, the Netherlands)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flow-controlled ventilation (FCV)
Description: 20 minutes of FCV, delivered with the CE-marked Evone ventilator (Ventinova medical, the Netherlands)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional volume-controlled ventilation (VCV)
Description: 20 minutes of conventional VCV, delivered with the CE-marked Aisys CS3 (GE Healthcare, USA) or Flow-i (Getinge, Sweden) ventilators.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional volume-controlled ventilation (VCV)
Description: 20 minutes of conventional VCV, delivered with the CE-marked Aisys CS3 (GE Healthcare, USA) or Flow-i (Getinge, Sweden) ventilators.
Study: NCT05626894

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: StrokeWear Motor and Behavioral Intervention
Description: The intervention will consist of 1) the use of StrokeWear for goal directed movements (GDM) feedback and goal setting, 2) use of daily activity action planning (DAAP) to foster planned hemiparetic UE use during daily activities in the home and community, and 3) patient empowerment. Patient empowerment in this study will occur over 6-months as patients gain the ability to use the StrokeWear technology independently and develop skills to manage their GDM and DAAP.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Usual Care
Description: The intervention will consist in a sham version of the StrokeWear system and usual clinical care under the direction of a clinician. The sham version of the StrokeWear system will include sensing and recording technology to detect GDMs. However, study participants will not receive feedback from the system regarding the GDM counts.
Study: NCT06011629

Intervention type: DEVICE
Group type: OTHER
Intervention: Aquacel dressing
Description: Patients will be recruited into the study after completing a standard questionnaire for pre-operative enrollment. After meeting inclusion criteria and passing the screening process, the patient will be enrolled into the study. Arthroplasty-naïve patients will be compared to prior total joint arthroplasty patients who received a Aquacel dressing postoperatively.
Study: NCT05194345

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: We Can! enhanced usual care
Description: We Can! EUC control group will spend about 3 hours over 5 months (baseline, post intervention, and 5-month follow-up assessments are 30 minutes each, one 25-30 minute nutrition session, and a 60-minute exit interview). We Can! EUC control group EI provider will spend about 4.5 hours over 5 months (two 90-minutes training sessions, one 25-30 minutes session, 1-2-minute written material distribution at their 9 weekly EI sessions, and a 60-minute exit interview).
Study: NCT06594913

Intervention type: OTHER
Intervention: Eating disorder diagnosis group
Description: This is an observational study, no active intervention is applied. Participants are assigned to an eating disorder diagnosis group based on their lifetime history of disordered eating behaviors and symptoms.

Intervention type: OTHER
Intervention: Eating disorder diagnosis group
Description: This is an observational study, no active intervention is applied. Participants are assigned to an eating disorder diagnosis group based on their lifetime history of disordered eating behaviors and symptoms.

Intervention type: OTHER
Intervention: Eating disorder diagnosis group
Description: This is an observational study, no active intervention is applied. Participants are assigned to an eating disorder diagnosis group based on their lifetime history of disordered eating behaviors and symptoms.

Intervention type: OTHER
Intervention: Eating disorder diagnosis group
Description: This is an observational study, no active intervention is applied. Participants are assigned to an eating disorder diagnosis group based on their lifetime history of disordered eating behaviors and symptoms.

Intervention type: OTHER
Intervention: Eating disorder diagnosis group
Description: This is an observational study, no active intervention is applied. Participants are assigned to an eating disorder diagnosis group based on their lifetime history of disordered eating behaviors and symptoms.
Study: NCT06141499

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider educational materials
Description: Dialysis providers will receive educational material about the kidney transplantation and waitlisting process.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient letters
Description: Dialysis patients will receive letters with information about their status within the kidney transplantation and waitlisting process. Letters will describe kidney waitlist status, living donor transplantation, Hepatitis C positive kidney transplants, and high Kidney Donor Profile Index (KDPI) transplants.
Study: NCT04921189

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The combined supplement of Ascorbic acid, Thiamine, and Cortisol
Description: The combined administration of 3 drugs will be mixed in a 50 mL 0.9% saline bag respectively and administered through intravenous infusion over 60 min every 12 h for 3 days.~1. Ascorbic acid (Ascorbic acid Inj \[500mg\]®): 50 mg/kg, maximum single dose 3 g, daily dose 6 g~2. Thiamine (Thiamine hcl inj \[50mg\]®): 200 mg~3. Cortisol (Cortisolu inj \[100mg\]®): 100mg (The main exposure was corticosteroid therapy, defined as the use of systemic corticosteroids. But if unavailable, it could be converted to hydrocortisone-equivalent doses (methylprednisolone 1:5, dexamethasone 1:25, prednisolone 1:4).)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An identical volume of 0.9% saline (150mL) administered through intravenous infusion over 60 min every 12 h for 3 days.
Study: NCT06656104

Intervention type: DEVICE
Intervention: Reference strategy
Description: Routine strategy based on the usual catheters and infusion systems used during the reference period

Intervention type: DEVICE
Intervention: Experimental strategy
Description: EDELVAISS multi-infusion strategy as routine strategy during the experimental period
Study: NCT04626362

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cranberry juice
Description: Cranberry juice cocktail will be provided by Ocean Spray Cranberries, Inc.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo juice
Description: Apple juice added with flavor and colorants will be provided by Ocean Spray Cranberries, Inc.
Study: NCT06651632

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aquablation Therapy
Description: The AquaBeam Robotic System and the HYDROS Robotic System utilize high-velocity sterile saline waterjet to resect prostate tissue, guided by real-time visualization through cystoscopy and transrectal ultrasound imaging. This minimally invasive surgical procedure is called the Aquablation therapy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical Prostatectomy
Description: Radical prostatectomy is a surgery that is performed through an incision in the lower abdomen or perineum, or with a laparoscope or robotic system to remove the entire prostate gland.
Study: NCT06605027

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Ketogenic Diet
Description: 2 week induction to establish ketosis followed by 12 weeks therapeutic ketogenic diet
Study: NCT06604364

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hypno VR
Description: pre-surgery sedation using virtual reality headset
Study: NCT06655220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin hydrochloride
Description: Metformin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin hydrochloride
Description: Metformin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1815368
Description: BI 1815368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1815368
Description: BI 1815368
Study: NCT06656507

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadro Iliac Plane Block (QIPB)
Description: The Quadro Iliac Plane Block (QIPB) will be performed pre-awakening in patients undergoing lumbar vertebra surgeries. Using a low-frequency convex ultrasound transducer (2-6 MHz), the spinal process will be identified at the L3 level in a prone-positioned patient. The transducer will be moved laterally to locate the transverse process within the erector spinae muscle and then rotated to the parasagittal plane to identify the Quadratus Lumborum Muscle (QLM) attachment to the iliac crest. A 22G x 100 mm block needle will be advanced under ultrasound guidance, and 50 mg (0.25%) bupivacaine will be injected bilaterally into the fascia beneath the QLM. This technique is designed to provide effective postoperative pain control by blocking the nerves in the quadratus lumborum plane.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block (ESP)
Description: The Erector Spinae Plane Block (ESP) will also be performed pre-awakening. A linear ultrasound probe will be placed transversely at the level of the L3 vertebra to visualize the transverse process. A block needle will be advanced under ultrasound guidance until it touches the transverse process, after which the needle will be withdrawn 1 mm. Fifty milligrams (0.25%) bupivacaine will then be administered bilaterally. The ESP block aims to provide postoperative analgesia by blocking sensory nerves in the erector spinae plane.
Study: NCT06150300

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehab program
Description: Exercise videos, breathing exercises, and educational messages delivered virtually

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Breathing exercises and educational messages
Study: NCT06662539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Petrelintide
Description: Petrelintide will be taken by participants once weekly as a self-administered subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Petrelintide
Description: Petrelintide will be taken by participants once weekly as a self-administered subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Petrelintide
Description: Petrelintide will be taken by participants once weekly as a self-administered subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Petrelintide
Description: Petrelintide will be taken by participants once weekly as a self-administered subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Petrelintide
Description: Petrelintide will be taken by participants once weekly as a self-administered subcutaneous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to petrelintide will be taken by participants once weekly as a self-administered subcutaneous injection.
Study: NCT04252677

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Obesity Prevention
Description: This intervention includes content specific to obesity behaviors-related health information, motivation, and behavioral skills.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Obesity Prevention
Description: This intervention includes content specific to obesity behaviors-related health information, motivation, and behavioral skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Literacy
Description: This intervention includes content specific to improving health literacy.
Study: NCT05497453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX-2002
Description: OTX-2002 is a lipid nanoparticle (LNP) that contains a biscistronic mRNA that codes for 2 independent epigenomic controllers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX-2002
Description: OTX-2002 is a lipid nanoparticle (LNP) that contains a biscistronic mRNA that codes for 2 independent epigenomic controllers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX-2002
Description: OTX-2002 is a lipid nanoparticle (LNP) that contains a biscistronic mRNA that codes for 2 independent epigenomic controllers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX-2002
Description: OTX-2002 is a lipid nanoparticle (LNP) that contains a biscistronic mRNA that codes for 2 independent epigenomic controllers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitor One
Description: Tyrosine Kinase Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitor Two
Description: tyrosine kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Checkpoint Inhibitor, Immune
Description: monoclonal antibody that binds to PD-1 or PD-L1
Study: NCT05926648

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00061
Description: Noninvasive pulse oximetry and pulse rate device
Study: NCT05726487

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACTION Intervention
Description: Participants in the ACTION Intervention arm of the study will have group sessions, physical activity self-monitoring, text-based support for goal setting. Following this intervention participants will be followed for an additional 24-weeks to assess for the maintenance of intervention effects on asthma health outcomes.

Intervention type: OTHER
Group type: OTHER
Intervention: Education Control
Description: Participants in the Education Control arm of the study will receive and individual asthma education session and text messages related to asthma education. Following this intervention participants will be followed for an additional 24-weeks to assess for the maintenance of intervention effects on asthma health outcomes.
Study: NCT06661694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Single 875 mg dose of mevrometostat standard tablet formulation
Study: NCT06386380

Intervention type: OTHER
Intervention: Rheumatic diseases Mistreatment Scale (RDMS)
Description: In 2012, Giraldo-Rodríguez developed and validated the Geriatric Mistreatment Scale (GAS); translation, cultural adaptation, and validation were performed prior to its application.

Intervention type: OTHER
Intervention: Routine assessment of patient index data 3 (RAPID-3)
Description: RAPID- 3 measures: function, pain, and patient global status estimate. Each of the three individual measures is scored 0 to 10, for a total of 30

Intervention type: OTHER
Intervention: Health Assessment Questionnaire (HAQ)
Description: The HAQ is based on five patient-centered dimensions: disability, pain, medication effects, costs of care, and mortality.

Intervention type: OTHER
Intervention: WHOQOL-BREF
Description: WHOQOL-BREF is a 26-item instrument consisting of four domains: physical health, psychological health, social relationships, and environmental health; it also contains QOL and general health items

Intervention type: OTHER
Intervention: Depression, Anxiety and Stress Scale (DASS-21)
Description: DASS-21 is a set of three self-report scales designed to measure the emotional states of depression, anxiety, and stress. Each of the three DASS-21 scales contains seven items, divided into subscales with similar content.

Intervention type: OTHER
Intervention: Brief Resilient Coping Scale
Description: The Brief Resilient Coping Scale is a 4-item measure designed to capture tendencies to cope with stress in a highly adaptive manner.

Intervention type: GENETIC
Intervention: Expression of CDKN2A /p16INK4a
Description: CDKN2A/p16INK4a expression will be measured using the Taqman qPCR assay (TaqMan Universal Master Mix II, with UNG, Applied Biosystems, Foster City, USA) according to the manufacturer's specifications.

Intervention type: OTHER
Intervention: Immunophenotype of leukocyte subpopulations
Description: CD4+ and CD8+ subpopulations will be analyzed. Blood samples will be analyzed by 8-color flow cytometry (Becton Dickinson Canto II cytometer) using fluorescently labeled antibodies from Biolegend Inc. (San Diego, USA).

Intervention type: GENETIC
Intervention: Telomere length
Description: The rLTL will be estimated by quantitative monochromatic multiplex PCR (MM-qPCR). Integrated DNA Technologies, Inc. (IDT, Coralville, IA, USA) will synthesize the primers used for telomere measurements.

Intervention type: OTHER
Intervention: Cellular senescence
Description: Expression of co-stimulatory molecules and surface receptors CD27- and CD28-
Study: NCT05748964

Intervention type: PROCEDURE
Intervention: Laparoscopic pyeloplasty
Description: Twenty patients presented with ureteropelvic junction obstruction \[UPJO\] will be divided into two equal groups. The first was subjected to trans-peritoneal pyeloplasty while the second was subjected to retroperitoneal pyeloplasty.

Intervention type: PROCEDURE
Intervention: Laparoscopic pyeloplasty
Description: Twenty patients presented with ureteropelvic junction obstruction \[UPJO\] will be divided into two equal groups. The first was subjected to trans-peritoneal pyeloplasty while the second was subjected to retroperitoneal pyeloplasty.
Study: NCT06572163

Intervention type: DEVICE
Group type: OTHER
Intervention: Eximis CS (Contained Segmentation) System
Description: The Eximis CS System is an integrated system consisting of a 900 mL Capture Bag, Inflation Mechanism, two Eximis Segmenters, and the Eximis RF Generator.
Study: NCT05728333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirofiban
Description: Intravenous tirofiban before endovascular thrombectomy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase
Description: Intravenous alteplase before endovascular thrombectomy.
Study: NCT04976439

Intervention type: OTHER
Intervention: co-occuring mutation
Description: APC, TP53, PIK3CA, KRAS APC, TP53, PIK3CA, MLH1 APC, TP53, PIK3CA, KRAS, and MLH1 APC, TP53, PIK3CA

Intervention type: OTHER
Intervention: co-occuring mutation
Description: APC, TP53, PIK3CA, KRAS APC, TP53, PIK3CA, MLH1 APC, TP53, PIK3CA, KRAS, and MLH1 APC, TP53, PIK3CA

Intervention type: OTHER
Intervention: co-occuring mutation
Description: APC, TP53, PIK3CA, KRAS APC, TP53, PIK3CA, MLH1 APC, TP53, PIK3CA, KRAS, and MLH1 APC, TP53, PIK3CA

Intervention type: OTHER
Intervention: co-occuring mutation
Description: APC, TP53, PIK3CA, KRAS APC, TP53, PIK3CA, MLH1 APC, TP53, PIK3CA, KRAS, and MLH1 APC, TP53, PIK3CA

Intervention type: OTHER
Intervention: co-occuring mutation
Description: APC, TP53, PIK3CA, KRAS APC, TP53, PIK3CA, MLH1 APC, TP53, PIK3CA, KRAS, and MLH1 APC, TP53, PIK3CA
Study: NCT05660382

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Miconazole (2%) oil and mineral oil
Description: Twice daily application, for 14 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice daily application, for 14 days